The AML Global Portal (AGP) was founded by the European Leukemia Net (ELN), and is steered by 35 worldwide experts in Acute Myeloid Leukemia (AML). The AGP provides the latest treatment options, medical information, case studies, recommendations, and expert opinions to support academic researchers and treating clinicians in making informed decisions, ensuring patients have access to the latest therapies available.

Our mission is to expedite learning and disseminate worldwide, the most up-to-date information on AML, amongst academic researchers and treating clinicians, to improve their understanding of the latest advances in terms of basic research and treatment options.

Digital Prospectus

If you would like to read further about the AML Global Portal or share the information with a colleague, please find the prospectus below

Download Here

Contact information

You can get in touch with us through our social media channels below:

Our supporters

At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

Platinum supporter
Silver supporters
Bronze supporters

Our sister hubs

Visit our other community physician education hubs in haematology and oncology

Scientific Education Support (SES)

The AML Global Portal is delivered by Scientific Education Support (SES) (company registration number 10636659). The registered office is 3 AC Court, High Street, Thames Ditton, Surrey, KT7 0SR, UK.